Risk factors for atherosclerotic cardiovascular disease (ASCVD) in healthcare professionals of Azar Cohort Study: A cross-sectional Study

Neda Roshanravan ^1,2 , Helda Tutunchi ³, Rezayat Parvizi ², Sepideh Bastani ⁴, Mohammad Asghari Jafarabadi ^5,6,7,8, Elnaz Faramarzi ⁹, Naimeh Mesri Alamdari ³ , Zohreh Ghoreishy ¹⁰, Faezeh Tarighat ¹¹, Kazem Mehravani ², Milad Vahedinezhad ¹², Nazli Namazi ¹³ * , Samad Ghaffari ² *

Cited by CrossRef: 0

1- Naderi N, fardesharifi M, Allahverdi D, Poustchi H, Yari Z. Independent and Combined Association of Overweight and Obesity and Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) with 10-Year Atherosclerotic Cardiovascular Disease Risk in Patients with Type 2 Diabetes. Iranian J Nutr Sci Food Technol. 2026;21(1):23 [Crossref]

2- Ruhela N, Singla A, Trivedi Y, Ahmed M, Chikatimalla R, Gupta S, Jain R. Advancements in lipid-lowering therapy: the role of proprotein convertase subtilisin/kexin type 9 inhibitors and beyond in cardiovascular risk reduction. 2025;36(8):696 [Crossref]

3- Talkhan A, Elkasaby M, Abou Elezz A, Borham N, Abbas A, Abbas A, Hammad N, Khalefa K, Shehata M. Comparative efficacy and safety of orally administered PCSK9 inhibitors in patients with Hypercholesterolaemia: a dose-stratified systematic review and network meta-analysis. Endocrine. 2026;91(1) [Crossref]